| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.13 | 0.007 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | -0.11 | 0.01 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.12 | 0.02 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | -0.084 | 0.07 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | -0.076 | 0.08 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.078 | 0.08 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | -0.071 | 0.09 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.068 | 0.1 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | -0.066 | 0.2 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.059 | 0.2 |